Mark Alexander Zubriski
- Associate Clinical Professor, Biomedical Informatics
- Associate Clinical Professor, Internal Medicine
- Associate Program Director, BMI Fellowship
Contact
- (602) 827-2324
- Biosciences Partnership Phx, Rm. 9TH FL
- Phoenix, AZ 85004
- zubriski@arizona.edu
Bio
No activities entered.
Interests
No activities entered.
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Maghari, S., Gallo, T., Rivas, S., German, A., Nguyen Le, M., Abbaszadegan, H., Zubriski, M., Heise, C., & Landas, N. (2023). Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients. Pharmacogenomics, 24(9). doi:10.2217/pgs-2023-0018More infoAim: To evaluate the prevalence of medications with actionable pharmacogenomic (PGx) safety and efficacy recommendations in patients receiving care from the Veterans Health Administration. Materials & methods: Outpatient prescription data from 2011 to 2021 and any documented adverse drug reactions (ADRs) were reviewed for those who received PGx testing at one Veterans Administration location between November 2019 and October 2021. Results: Among the reviewed prescriptions, 381 (32.8%) were associated with an actionable recommendation based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) prescribing guidelines, with 205 (17.7%) for efficacy concerns and 176 (15.2%) for safety concerns. Among those with a documented ADR for a PGx-impacted medication, 39.1% had PGx results that aligned with CPIC recommendations. Conclusion: Medications with actionable PGx recommendations for safety and efficacy concerns are received with similar frequency, and most patients who have undergone PGx testing at the Phoenix Veterans Administration have received medications that may be impacted by PGx testing.
